Drugs / FRSW107
FRSW107
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05251090 | Jun → Nov 2021 | hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06136507 | Dec 2026 expected | severe hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07684898 | Jun 2026 → Mar 2027 expected | severe hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07663903 | Apr 2026 → Feb 2027 expected | severe hemophilia A | Hangzhou Gensciences Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04456387 | Oct 2020 → Sep 2021 | hemophilia A | Zhengzhou Gensciences Inc | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FRSW107 | “Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107)” NCT04456387 ↗ |
| Known as | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection | “Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107)” NCT04456387 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Coagulation Factor VIII-Fc Fusion Protein” NCT04456387 ↗ |